polycystic ovary syndrome (PCOS)
Conditions
Interventions
Study Group:None
Control Group:None
Sponsors
Sichuan Maternal and Child Health Hospital
Eligibility
Sex/Gender
Female
Age
20 Years to 37 Years
Inclusion criteria
Inclusion criteria: Study Group: (1) Meet the 2003 Rotterdam diagnostic criteria for PCOS (fulfill at least two of the following): 1). Oligo-ovulation or anovulation 2). Clinical and/or biochemical signs of hyperandrogenism 3). Polycystic ovarian morphology (PCOM) on ultrasound (2) Age 20-37 years; (3) Normal semen parameters in partner (per WHO 6th edition); (4) Meet indications for IVF-assisted reproduction; (5) Normal karyotype analysis in both partners; Control Group: (1) Diagnosed with tubal obstructive infertility by hysterosalpingography (HSG) or laparoscopy; (2) Regular menstrual cycles (21-35 days); (3) Normal serum sex hormone levels (FSH<10 IU/L, LH<10 IU/L, E2 20-300 pg/mL); (4) Normal uterine/ovarian structure on ultrasound (absence of PCOM features); (5) Age 20-37 years; (6) Normal semen parameters in partner (per WHO 6th edition); (7) Meet indications for IVF-assisted reproduction; (8) Normal karyotype analysis in both partners;
Exclusion criteria
Exclusion criteria: Exclusion Criteria (Both Groups): (1)Failure to meet the aforementioned inclusion criteria; (2)Other disorders causing hyperandrogenism or ovulatory dysfunction (e.g., androgen-secreting tumors, non-classic adrenal hyperplasia); (3)Severe systemic diseases, including:Uncontrolled cardiovascular, hepatic, or renal dysfunction;Active malignancy or autoimmune disorders; (4)Unwillingness/inability to provide informed consent or comply with study procedures. (5)Comorbidities confounding assessments:Immunodeficiency disorders; Ovarian tumors or genital tract malformations; (6)Concurrent participation in other interventional trials or treatments that may interfere with study outcomes; (7)History of hypersensitivity to BPA-related compounds or multiple drug allergies (>=3 classes); (8)Recent interventions affecting endocrine/reproductive status: Hormonal medication use (contraceptives, glucocorticoids, etc.) within 6 months; Intrauterine procedures (e.g., hysteroscopy) within 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical pregnancy rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Fertilized oocytes (2PN);No. of MII oocytes ;No. of available embryos of Day 3;Rate of high quality blastocysts;Pregnancy rate;Miscarriage rate; | — |
Countries
China
Contacts
Public ContactJiuzhi Zeng
Sichuan Maternal and Child Health Hospital
Outcome results
None listed